Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optate
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Inhalation, Intranasal
01
Overview
Optate is an investigational inhaled medication designed to safely raise airway surface pH and intracellular pH. This mechanism of action has been shown to inhibit the replication of respiratory viruses, including SARS-CoV-2 and Respiratory Syncytial Virus (RSV), by preventing viral activation and decreasing viral replication. It also inhibits the expression of major endosomal trafficking genes, which contributes to its antiviral effects. Optate is being investigated as a potential treatment for COVID-19 and RSV, with studies suggesting it could reduce symptom length and disease severity. It has been well tolerated in healthy human subjects during a Phase 2a safety trial.
Beyond the preview
Go deeper on Optate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optate.